Skip to main content
OpenTrials
Completed

NCT Number: NCT07023055

Serum TAM Receptor Tyrosine Kinase Ligands in Acute Pancreatitis

AXL and MERTK are homologous members of the TAM (TYRO3, AXL, MERTK) receptor tyrosine kinase family. They function as critical regulators of antiviral immunity, autoimmune responses, and tumor microenvironment modulation through their bridging ligands, GAS6 (Growth Arrest-Specific 6) and PROS1 (Protein S). These receptors serve as damage sensors that negatively regulate inflammation, promote tissue repair/remodeling, and modulate fibrotic processes in chronic inflammatory conditions. Building upon our previous work demonstrating the pivotal role of the AXL/MERTK signaling axis in AP pathogenesis - particularly in pancreatic necrosis regulation, this clinical study seeks to evaluate the prognostic value of the TAM receptor ligands GAS6 and PROS1 as biomarkers for predicting AP severity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Pancreatic Necrosis Acute Pancreatitis (AP) Digestive System Diseases Pancreatic Diseases Pancreatitis

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-80 years.
  • Patients diagnosed with acute pancreatitis in outpatient/emergency departments, inpatient wards, or health examination centers starting from 2024.

Exclusion criteria

  • Patients with chronic pancreatitis or pancreatic cancer.
  • Pregnant or lactating women.
  • Patients who did not provide informed consent.
  • Patients with severe organic diseases, such as malignant tumors, acute myocardial infarction, or large-scale cerebral infarction.

Treatment and study plan

Primary outcomes

  1. Proportion of Participants with Severe Acute Pancreatitis

    Time frame: 2 days

    AP severity was classified as mild (MAP), moderately severe (MSAP), or severe (SAP) according to the revised Atlanta classification.

Secondary outcomes

  1. Incidence Rate of Persistent Organ Failure (≥48 Hours) in Acute Pancreatitis

    Time frame: 2 days

    Organ dysfunction in acute pancreatitis refers to the impairment of one or more organ systems (e.g., respiratory, renal, cardiovascular) due to systemic inflammation, often leading to persistent organ failure (≥48 hours), a hallmark of severe acute pancreatitis (SAP).

Sponsors and collaborators

Lead sponsor

Peking Union Medical College Hospital

Other

Collaborators

  • The first affiliated Hospital of Nanjing Medical University, Jiangsu Province

Registry information

Official study title

Multicenter Prospective Cohort Study on TAM Receptor Tyrosine Kinase Ligands for Predicting the Severity of Acute Pancreatitis

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jun 15, 2025
Registry last updated
Jun 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.